PDH inhibitor CPI‐613 has been approved by FDA for clinical trials for pancreatic cancer treatment.[23] Previous study also indicated that the PC inhibitor CHCA (α‐cyano‐4‐hydroxycinnamic acid) effectively suppressed breast cancer in vivo.[24] Similar results could be observed when MHCC97L cells were treated with PDH or PC inhibitor and glutaminase (GLS) inhibitor BPTES (Figure S3A,B, Supporting Information). This evidence concerns the gene GLS and pancreatic neoplasm.